Nathaniel M. Lacktman | Source | Equity Partner at Foley & Lardner LLP
Nathaniel M. Lacktman
Nathaniel is an Equity Partner at Foley & Lardner, LLP. He advises entrepreneurial health care providers and technology companies on business arrangements, compliance, and corporate matters in telemedicine, digital health, remote patient monitoring, and click-and-mortar services. Working with hospitals, health systems, providers, and start-ups to build telemedicine arrangements across the United States, Nathaniel's practice emphasizes strategic counseling, creative business modeling, and fresh approaches to realize clients' ambitious and innovative goals.
-
The proposed rules are intended to bridge between the DEA’s current PHE waivers and a post-PHE environment. In so doing, DEA proposed creating two new limited options for telemedicine prescribing of controlled substances without a prior in-person exam. The options [are] both complex and more restrictive than what has been allowed for the past three years under the PHE waivers.
-
Foley Telemedicine Attorneys Quoted on DEA PHE Waiver Extension | Foley & Lardner LLP
Foley & Lardner LLP Partners Nathaniel Lacktman, Thomas Ferrante, and Rachel Goodman are quoted in the HealthLeaders article, “DEA Extends Telemedicine Prescription Waivers by 6 Months.”
Article
-
Foley & Lardner LLP
Equity Partner